WallStSmart

AstraZeneca PLC (AZN)vsSTERIS plc (STE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 916% more annual revenue ($61.37B vs $6.04B). AZN leads profitability with a 17.0% profit margin vs 13.3%. AZN appears more attractively valued with a PEG of 1.28. STE earns a higher WallStSmart Score of 60/100 (C).

AZN

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.7Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

STE

Buy

60

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 8.0
Piotroski: 7/9Altman Z: 2.65
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+18.4%)

Margin of Safety

+18.4%

Fair Value

$196.10

Current Price

$160.17

$35.93 discount

UndervaluedFair: $196.10Overvalued
STESignificantly Overvalued (-48.8%)

Margin of Safety

-48.8%

Fair Value

$163.58

Current Price

$210.76

$47.18 premium

UndervaluedFair: $163.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$252.33B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

STE2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

AZN2 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

STE2 concerns · Avg: 4.0/10
PEG RatioValuation
1.874/10

Expensive relative to growth rate

P/E RatioValuation
26.7x4/10

Moderate valuation

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.

Bull Case : STE

The strongest argument for STE centers on Debt/Equity, Price/Book.

Bear Case : AZN

The primary concerns for AZN are EPS Growth, Altman Z-Score.

Bear Case : STE

The primary concerns for STE are PEG Ratio, P/E Ratio.

Key Dynamics to Monitor

AZN profiles as a mature stock while STE is a value play — different risk/reward profiles.

STE carries more volatility with a beta of 0.91 — expect wider price swings.

STE is growing revenue faster at 7.3% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (60/100 vs 60/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

STERIS plc

HEALTHCARE · MEDICAL DEVICES · USA

Steris Corporation is an American Irish-domiciled medical equipment company specializing in sterilization and surgical products for the US healthcare system.

Want to dig deeper into these stocks?